Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2E (CMT2E) is a form of axonal Charcot-Marie-Tooth disease, a peripheral sensorimotor neuropathy. CMT2E onset is in the first to 6th decade with a gait anomaly and a leg weakness that reaches the arms secondarily. Tendon reflexes are reduced or absent and, after years, all patients have a pes cavus. Other signs may be present, including hearing loss and postural tremor.
Features include always present findings: Distal sensory impairment, Impaired pain sensation, Onion bulb formation, and Areflexia and others; and very common findings: Lower limb muscle weakness, Difficulty walking (gait disturbance), Abnormal foot morphology, and Peripheral axonal neuropathy and others. 45 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 11 | Flexion contracture, Distal muscle weakness, Lower limb muscle weakness |
NEFL encodes neurofilament light chain (543 aa). Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. Highest expression in Brain Frontal Cortex BA9 (487.2 TPM) and Brain Cortex (328.6 TPM).
Charcot-Marie-Tooth disease type 2E is associated with mutations in the NEFL gene on chromosome 8.
The NEFL protein participates in Transcription of NOTCH2NLB gene, GRIN1:GRIN2B NMDA receptors:DLG4:DLG1,DLG2,DLG3,DLG4:NEFL, and GRIN1:GRIN2 NMDA receptors:DLG4:DLG1,DLG2,DLG3,DLG4:NEFL pathways.
NEFL is classified as a druggable target with score 0.0.
Genetic testing for NEFL is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Charcot-Marie-Tooth disease type 2E has been reported in the published literature.
Phenotype severity distribution: 5 always present features, 8 very common features, 18 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
8 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 2E. Research spans Basic Science / Preclinical (63%), Gene Therapy / Novel Therapeutics (25%), and Diagnostic / Biomarker (13%).
Dua PH (2026). [PMID: 41267399](https://pubmed.ncbi.nlm.nih.gov/41267399/). *Mol Ther*. [Gene Therapy / Novel Therapeutics]
Abati E (2026). [PMID: 42020662](https://pubmed.ncbi.nlm.nih.gov/42020662/). *Sci Rep*. [Diagnostic / Biomarker]
Pérez-López DO (2025). [PMID: 39975190](https://pubmed.ncbi.nlm.nih.gov/39975190/). *bioRxiv*. [Basic Science / Preclinical]
Pérez-López DO (2025). [PMID: 40635134](https://pubmed.ncbi.nlm.nih.gov/40635134/). *Hum Mol Genet*. [Basic Science / Preclinical]
Pérez-López DO (2025). [PMID: 40413792](https://pubmed.ncbi.nlm.nih.gov/40413792/). *Hum Mol Genet*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 3:05 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 2E
Brain and nerves | 8 | Steppage gait, Hyporeflexia, Difficulty walking (gait disturbance) |
Arms and legs | 8 | Lower limb muscle weakness, Foot dorsiflexor weakness, Distal upper limb muscle weakness |
Head and neck | 2 | Facial palsy, High palate |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
Eyes | 1 | Ptosis |
Lab test results | 1 | Extremely elevated creatine kinase |
Pérez-López DO (2025). [PMID: 39975380](https://pubmed.ncbi.nlm.nih.gov/39975380/). *bioRxiv*. [Basic Science / Preclinical]
Rice AD (2025). [PMID: 40833344](https://pubmed.ncbi.nlm.nih.gov/40833344/). *J Peripher Nerv Syst*. [Basic Science / Preclinical]
Medina J (2024). [PMID: 39008620](https://pubmed.ncbi.nlm.nih.gov/39008620/). *Brain*. [Gene Therapy / Novel Therapeutics]